Search results for "pneu"

showing 10 items of 900 documents

Rapid, cost-effective, sensitive and quantitative detection of Acinetobacter baumannii from pneumonia patients

2011

Background and Objectives: Pneumonia with Acinetobacter baumannii has a major therapeutic problem in health care settings. Decision to initiate correct antibiotic therapy requires rapid identification and quantification of organism. The aim of this study was to develop a rapid and sensitive method for direct detection of A. baumannii from respiratory specimens. Materials and Methods: A Taqman real time PCR based on the sequence of blaoxa-51 was designed and used for direct detection of A. baumannii from 361 respiratory specimens of patients with pneumonia. All specimens were checked by conventional bacteriology in parallel. Results: The new real time PCR could detect less than 200 cfu per m…

Acinetobacter baumanniiReal time PCRSettore MED/07 - Microbiologia E Microbiologia Clinicalcsh:QR1-502VAPHAPPneumoniaHAP VAP Acinetobacter baumannii Real time PCR Pneumonialcsh:Microbiology
researchProduct

Drug resistance patterns of bacteria isolated from patients with nosocomial pneumonia at Tehran hospitals during 2009-2011

2013

Introduction: Nosocomial pneumonia remains an important cause of mortality and morbidity worldwide. Surveillance programs play an important role in the identification of common etiologic agents and local patterns of antimicrobial resistance. Methodology: In this study we determined the frequency and antimicrobial susceptibility of pathogens isolated from patients with nosocomial pneumonia during 2009 to 2011. Results: A total of 642 bacteria were isolated from 516 suspected samples. Acinetobacter baumannii (21.1%, n = 136), was the commonest isolated pathogen followed by Pseudomonas aeruginosa (17.4%, n = 112) , Staphylococcus aureus (15.8%, n = 102) and enterococci (8.4% n = 54). The most …

Acinetobacter baumanniiSettore MED/07 - Microbiologia E Microbiologia ClinicaPenicillanic AcidDrug resistanceIranmedicine.disease_causechemistry.chemical_compoundLevofloxacinDrug Resistance Multiple BacterialPrevalenceRespiratory Tract InfectionsPolymyxin BCross InfectionbiologyCeftriaxoneGeneral MedicineHospitalsAcinetobacter baumanniiAnti-Bacterial AgentsInfectious DiseasesPiperacillin Tazobactam Drug CombinationPseudomonas aeruginosaCeftriaxonemedicine.drugMethicillin-Resistant Staphylococcus aureusStaphylococcus aureusMicrobial Sensitivity TestsMicrobiologyTazobactamMicrobiologyAntibiotic resistanceAcinetobacter baumanniiiVirologymedicinePneumonia BacterialHumansTehran hospitalsGram-Positive Bacterial InfectionsPiperacillindrug resistancebusiness.industryPseudomonas aeruginosanosocomial pneumoniaSputumbiochemical phenomena metabolism and nutritionbacterial infections and mycosesbiology.organism_classificationchemistrynosocomial pneumonia; drug resistance; Acinetobacter baumanniii; Pseudomonas aeruginosa; Tehran hospitalsLinezolidParasitologybusinessGram-Negative Bacterial Infections
researchProduct

High susceptibility of MDR and XDR Gram-negative pathogens to biphenyl-diacetylene-based difluoromethyl-allo-threonyl-hydroxamate LpxC inhibitors

2016

International audience; Inhibitors of uridine diphosphate-3-O-(R-3-hydroxymyristoyl)-N-acetylglucosamine deacetylase (LpxC, which catalyses the first, irreversible step in lipid A biosynthesis) are a promising new class of antibiotics against Gram-negative bacteria. The objectives of the present study were to: (i) compare the antibiotic activities of three LpxC inhibitors (LPC-058, LPC-011 and LPC-087) and the reference inhibitor CHIR-090 against Gram-negative bacilli (including MDR and XDR isolates); and (ii) investigate the effect of combining these inhibitors with conventional antibiotics.MethodsMICs were determined for 369 clinical isolates (234 Enterobacteriaceae and 135 non-fermentati…

Acinetobacter baumanniiThreonine0301 basic medicineMicrobiology (medical)Klebsiella pneumoniaemedicine.drug_class030106 microbiologyAntibioticsMicrobial Sensitivity TestsHydroxamic Acidsmedicine.disease_causebeta-LactamasesAmidohydrolasesMicrobiology03 medical and health sciencesBacterial ProteinsEnterobacteriaceae[ SDV.MP ] Life Sciences [q-bio]/Microbiology and ParasitologyDrug Resistance Multiple BacterialGram-Negative BacteriaEscherichia colipolycyclic compoundsmedicineHumansPharmacology (medical)Enzyme InhibitorsOriginal ResearchPharmacologybiologyPseudomonas aeruginosaEnterobacteriaceae Infectionsbiochemical phenomena metabolism and nutritionbacterial infections and mycosesAntimicrobialbiology.organism_classificationEnterobacteriaceaeAnti-Bacterial Agents3. Good healthAcinetobacter baumanniiCiprofloxacinKlebsiella pneumoniae[SDV.MP]Life Sciences [q-bio]/Microbiology and ParasitologyInfectious DiseasesAmikacinPseudomonas aeruginosalipids (amino acids peptides and proteins)medicine.drugJournal of Antimicrobial Chemotherapy
researchProduct

Sorveglianza attiva delle patologie pneumococciche invasive dell'età pediatrica: l’esperienza della Regione Sicilia nel triennio 2009-2011

2013

S.pneumoniae is a major cause of morbidity and mortality among children globally. Since 2007 the World Health Organization has recommended anti-pneumococcal vaccination to reduce the burden of invasive pneumococcal diseases (IPD). The aim of this study was to estimate the incidence of IPD in Sicilian children and describe the distribution of serotypes in subjects with IPD following the recent introduction of a universal vaccination program. Active surveillance of IPD (PneumoNet) was carried out in Sicily from 2009 to 2011 by nine reference hospitals (one per province) and one-hundred randomly sampled family pediatricians. Hospital discharge data of participating hospitals were also analyzed…

Active surveillanceMalattia Pneumococcica Invasiva Vaccinazione antipneumococcica Sorveglianza Età Pediatricapneumococcal diseases in Sicilian childrenSettore MED/42 - Igiene Generale E Applicatainvasive pneumococcal disease
researchProduct

Acute cholecystitis during COVID-19 pandemic: a multisocietary position statement

2020

AbstractFollowing the spread of the infection from the new SARS-CoV2 coronavirus in March 2020, several surgical societies have released their recommendations to manage the implications of the COVID-19 pandemic for the daily clinical practice. The recommendations on emergency surgery have fueled a debate among surgeons on an international level.We maintain that laparoscopic cholecystectomy remains the treatment of choice for acute cholecystitis, even in the COVID-19 era. Moreover, since laparoscopic cholecystectomy is not more likely to spread the COVID-19 infection than open cholecystectomy, it must be organized in such a way as to be carried out safely even in the present situation, to gu…

Acute cholecystitis; COVID-19 pandemic; Emergency surgery; New coronavirus; Position statement; Betacoronavirus; COVID-19; Cholecystectomy; Cholecystitis Acute; Coronavirus Infections; Humans; Infection Control; Pandemics; Pneumonia Viral; SARS-CoV-2; Societies Medical; Practice Guidelines as Topicmedicine.medical_treatmentCholecystitis AcutePosition statement030230 surgery0302 clinical medicinePandemicCholecystitisInfection control030212 general & internal medicineViralSocieties Medicallcsh:Medical emergencies. Critical care. Intensive care. First aidPractice Guidelines as TopicEmergency MedicineEmergency surgeryAcute cholecystitis Emergency surgery COVID-19 pandemic New coronavirus Position statementCoronavirus InfectionsHumanPosition statementmedicine.medical_specialtyCoronavirus disease 2019 (COVID-19)Pneumonia Virallcsh:SurgeryCOVID-19 pandemicNew coronaviruAcuteAcute cholecystitiacute cholecystitis; COVID-19 pandemic; emergency surgery; Nnew coronavirus; position statement; betacoronavirus; cholecystectomy; cholecystitis acute; coronavirus infections; humans; infection control; pandemics; pneumonia viral; societies medical; practice guidelines as topicNO03 medical and health sciencesBetacoronavirusEmergency surgeryMedicalmedicineAcute cholecystitisHumansCholecystectomyPandemicsAcute cholecystitis; COVID-19 pandemic; Emergency surgery; New coronavirus; Position statement; Betacoronavirus; Cholecystectomy; Cholecystitis Acute; Coronavirus Infections; Humans; Infection Control; Pandemics; Pneumonia Viral; Societies Medical; Practice Guidelines as TopicInfection ControlBetacoronaviruPandemicbusiness.industrySARS-CoV-2Coronavirus InfectionGeneral surgeryCOVID-19New coronavirusPneumonialcsh:RD1-811lcsh:RC86-88.9Acute cholecystitisSettore MED/18 - Chirurgia GeneraleInvasive surgeryCommentarySurgeryCholecystectomybusinessSocietiesWorld Journal of Emergency Surgery
researchProduct

Post-Infectious Myocardial Infarction: New Insights for Improved Screening

2019

Acute infection is suspected of involvement in the onset of acute myocardial infarction (MI). We aimed to assess the incidence, pathogenesis and prognosis of post-infectious MI. All consecutive patients hospitalized for an acute MI in coronary care units were prospectively included. Post-infectious MI was defined by a concurrent diagnosis of acute infection at admission. Type 1 MI (acute plaque disruption) or Type 2 MI (imbalance in oxygen supply/demand) were adjudicated according to the universal definition of MI. From the 4573 patients admitted for acute MI, 466 (10%) had a concurrent acute infection (median age 78 (66–85) y, 60% male), of whom 313 (67%) had a respiratory tract infection.…

Acute coronary syndromemedicine.medical_specialtylcsh:Medicine030204 cardiovascular system & hematologyType 2 myocardial infarctionelderlyArticleacute coronary syndromeSepsisPathogenesissepsis03 medical and health sciences0302 clinical medicineInternal medicinemedicinepneumonia030212 general & internal medicineMyocardial infarctionbusiness.industryIncidence (epidemiology)lcsh:Rpulmonary tract infectionGeneral MedicineOdds ratiomedicine.diseaseConfidence intervalinfectionPneumoniabusinessin-hospital mortalityJournal of Clinical Medicine
researchProduct

Viral exanthema as manifestation of SARS-CoV-2 infection

2020

Abstract Rationale: The clinical manifestations of the SARS-CoV-2 infection are mainly respiratory but the virus can cause a variety of symptoms. Dermatological findings are less well-characterized. Data is scarce on their timing, type and correlation with the immune response. Patient concerns: We present the case of SARS-CoV-2 infection in a previously healthy woman who presented with respiratory symptoms and developed anosmia, diarrhea, and an erythematous maculo-papular rash on day 15 from symptom onset. Diagnosis: The nasopharyngeal swab tested by real time PCR for COVID-19 was positive. We interpreted this as a viral exanthema likely caused by an immune response to SARS-CoV-2 nucleotid…

Administration TopicalvirusesAzithromycinAzithromycinLopinavirimmune responseCOVID-19 Testing0302 clinical medicine030212 general & internal medicineclinical manifestations4900virus diseasesLopinavirGeneral MedicineRashDrug CombinationsDiarrheaTreatment Outcome030220 oncology & carcinogenesisFemaleSymptom Assessmentmedicine.symptomCoronavirus InfectionsHydroxychloroquineResearch Articlemedicine.drugAdultmedicine.medical_specialtyPneumonia ViralAnosmiaAntiviral AgentsBetacoronavirus03 medical and health sciencesImmune systemImmunitymedicineHumansClinical Case ReportGlucocorticoidsPandemicsRitonavirClinical Laboratory TechniquesSARS-CoV-2business.industryfungiCOVID-19HydroxychloroquineExanthemabiochemical phenomena metabolism and nutritionDermatologybusinessanosmiaMedicine
researchProduct

TH17 cells mediate pulmonary collateral priming

2010

Background Our laboratory has shown that inhalational sensitization to new antigens is facilitated through an ongoing T H 2-polarized inflammation of the lung, a phenomenon we call "collateral priming." Objective We were interested to analyze whether a T H 1-polarized pulmonary inflammation also facilitates priming toward new antigens and which cytokine or cytokines are involved. Methods T H 1-polarized T cells were generated in vitro and transferred into congenic mice. Mice were challenged initially with cognate antigen and an unrelated antigen; consecutively, they received cognate antigen or the secondary antigen. Airway inflammation, antigen-specific IgG2a levels, and airway hyperrespons…

Adoptive cell transfermedicine.medical_treatmentImmunologyPriming (immunology)Mice TransgenicCell SeparationLymphocyte ActivationArticleAllergic sensitizationMiceAntigenmedicineAnimalsImmunology and AllergyCytotoxic T cellAntigen-presenting cellLungMice Inbred BALB Cbusiness.industryInterleukin-17PneumoniaFlow CytometryAdoptive TransferCytokineInhalationImmunologyTh17 CellsInterleukin 17Bronchial HyperreactivitybusinessJournal of Allergy and Clinical Immunology
researchProduct

The 2015 International Society for Heart and Lung Transplantation Guidelines for the management of fungal infections in mechanical circulatory suppor…

2016

Shahid Husain, MD, MS, Amparo Sole, MD, PhD, Barbara D. Alexander, MD, MHS, Saima Aslam, MD, MS, Robin Avery, MD, Christian Benden, MD, Eliane M. Billaud, PharmD, PhD, Daniel Chambers, MBBS, MD, Lara Danziger-Isakov, MD, Savitri Fedson, MD, Kate Gould, MD, Aric Gregson, MD, Paolo Grossi, MD, PhD, Denis Hadjiliadis, MD, Peter Hopkins, MD, Me-Linh Luong, MD, Debbie J.E. Marriott, MD, Victor Monforte, MD, Patricia Munoz, MD, PhD, Alessandro C. Pasqualotto, MD, PhD, Antonio Roman, MD, Fernanda P. Silveira, MD, Jeffrey Teuteberg, MD, MS, Stephen Weigt, MD, Aimee K. Zaas, MD, MHS, Andreas Zuckerman, MD, and Orla Morrissey, MD, PhD

Adult0301 basic medicinePulmonary and Respiratory Medicinemedicine.medical_specialty2747 TransplantationHeart-Lung Transplantation030106 microbiology610 Medicine & health030230 surgery2705 Cardiology and Cardiovascular Medicine03 medical and health sciencesPostoperative Complications0302 clinical medicinePrevalencemedicineHumansAssisted CirculationChildTransplantationbusiness.industryIncidence2746 SurgerySurgeryMycoses2740 Pulmonary and Respiratory MedicineAdult; Child; Humans; Incidence; Mycoses; Postoperative Complications; Prevalence; Assisted Circulation; Heart-Lung Transplantation; Surgery; Pulmonary and Respiratory Medicine; Cardiology and Cardiovascular Medicine; TransplantationSurgery10178 Clinic for PneumologyCardiology and Cardiovascular MedicinebusinessHumanitiesThe Journal of Heart and Lung Transplantation
researchProduct

A Trial of Lopinavir–Ritonavir in Covid-19

2020

Adult2019-20 coronavirus outbreakCoronavirus disease 2019 (COVID-19)Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Pneumonia ViralLopinavir/ritonavirPharmacologyLopinavirBetacoronavirusmedicineHumansPandemicsRitonavirBetacoronaviruPandemicCoronavirus InfectionSARS-CoV-2business.industryCOVID-19LopinavirGeneral MedicineCOVID-19 Drug TreatmentRitonavirCoronavirus InfectionsbusinessCoronavirus InfectionsHumanmedicine.drugNew England Journal of Medicine
researchProduct